Efficacy and Safety of High-Flow Nasal Cannula During Transcatheter Closure Procedures
Efficacy and Safety of High-Flow Nasal Cannula During Transcatheter Closure Procedures for Congenital Heart Disease
This study aims to evaluate the efficacy and safety of high-flow nasal cannula oxygen therapy, compared with standard nasal cannula oxygen therapy, as respiratory support during transcatheter closure procedures for congenital heart disease under non-intubated deep sedation.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Transcatheter closure is a standard treatment for selected congenital heart diseases and is often performed under deep sedation with transesophageal echocardiographic guidance. During non-intubated sedation, oxygen desaturation may occur due to airway collapse, respiratory depression, supine positioning, or limited cardiopulmonary reserve. Standard nasal cannula oxygen may be insufficient in high-risk patients, whereas HFNC provides heated, humidified high-flow oxygen, stable FiO2, dead-space washout, and mild positive airway pressure to improve oxygenation and airway stability. This study will enroll pediatric and adult patients undergoing transcatheter closure for congenital heart disease. Participants will be stratified by age and/or clinical risk and randomized to receive either HFNC or standard nasal cannula oxygen therapy. This study is expected to clarify whether HFNC can reduce intra-procedural oxygen desaturation, improve oxygenation stability, decrease emergency airway interventions, and maintain hemodynamic safety during deep sedation. The findings may support standardized respiratory support protocols in cardiac catheterization laboratories and provide evidence for individualized peri-procedural care in pediatric and adult congenital heart disease patients.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ke-Yun Chao, PhD
- Phone Number: +886905301879
- Email: 148540@mail.fju.edu.tw
Study Locations
-
-
-
New Taipei City, Taiwan, 24352
- Fu Jen Catholic University Hospital, Fu Jen Catholic University
-
Principal Investigator:
- Ke-Yun Chao, PhD
-
Contact:
- Ke-Yun Chao, PhD
- Phone Number: +886905301879
- Email: 148540@mail.fju.edu.tw
-
Yunlin, Taiwan
- National Taiwan University Hospital Yunlin Branch
-
Contact:
- Hīng-Ka Lîm, PhD
- Phone Number: +886972655716
- Email: linhsinchia@gmail.com
-
Principal Investigator:
- Hīng-Ka Lîm, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with a simple congenital heart defect, including an atrial septal defect, ventricular septal defect, patent ductus arteriosus, or patent foramen ovale, and scheduled for an elective transcatheter closure procedure.
- American Society of Anesthesiologists physical status classification I-III.
- Written informed consent.
Exclusion Criteria:
- Complex congenital heart disease.
- Severe anatomical abnormalities of the upper airway.
- Preprocedural severe cyanosis or hypoxemia, defined as an oxygen saturation below 90% while room air.
- A contraindication to high-flow nasal cannula, as determined by the physician.
- A skin condition over the chest that prevents placement of electrodes for noninvasive cardiac output monitoring.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: High-flow nasal cannula group
Receive high-flow nasal cannula during transcatheter closure procedures under deep sedation |
Heated, humidified high-flow oxygen will be delivered through a nasal cannula. |
|
Active Comparator: Conventional nasal cannula oxygen therapy
Receive conventional nasal cannula oxygen therapy during transcatheter closure procedures under deep sedation |
Oxygen will be delivered through a nasal cannula. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of hypoxemia
Time Frame: From initiation of the assigned oxygen therapy to completion of transcatheter closure procedure
|
Defined as at least one episode of peripheral oxygen saturation below 90% lasting at least 10 seconds |
From initiation of the assigned oxygen therapy to completion of transcatheter closure procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ke-Yun Chao, PhD, Fu Jen Catholic University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FJUH115607
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.